pembrolizumab
Pronunciation: PEM broe LIZ ue mab
Other Name(s): Keytruda®
Appearance: solution
mixed into larger bags of fluids
Drug Formulary information is intended for use by healthcare professionals. It is not intended to be medical advice. Some of the information, including information about funding for cancer drugs, does not apply to all patients. Cancer treatment plans are unique to each patient. If you are a patient, please speak with your healthcare team to understand how this information applies to you.
Drug Monograph
Sep 2025
Eligibility Forms
Pembrolizumab - Advanced or Metastatic Non-Small Cell Lung Cancer (Second or Subsequent Line) Pembrolizumab - Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma Pembrolizumab - Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer Pembrolizumab - Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Pembrolizumab (Adult and Pediatric) - Relapsed cHL Post-Autologous Stem Cell Transplant or ASCT Ineligible Pembrolizumab (Adult Who Failed Prior Brentuximab Vedotin) - Relapsed cHL Post-ASCT or ASCT Ineligible Pembrolizumab - In Combination with Axitinib for First Line Advanced or Metastatic Renal Cell Carcinoma Pembrolizumab - First Line Treatment of MSI-H dMMR Metastatic Colorectal Cancer Pembrolizumab - Adjuvant Treatment for Renal Cell Carcinoma Pembrolizumab - Previously Treated MSI-H dMMR Advanced Endometrial Cancer Pembrolizumab - In Combination with Lenvatinib for Advanced Endometrial Cancer Pembrolizumab - In Combination with Lenvatinib for First-Line Advanced or Metastatic Renal Cell Carcinoma Pembrolizumab - Locally Recurrent Unresectable or Metastatic Triple Negative Breast Cancer Pembrolizumab - Previously Untreated High-Risk Early-Stage Triple Negative Breast Cancer Pembrolizumab and Trastuzumab (Biosimilar) - First-line Treatment of Advanced HER2-Positive Gastric or Esophagogastric Junction Pembrolizumab - Locally Advanced Unresectable or Metastatic Biliary Tract Cancer Pembrolizumab - Metastatic Persistent or Recurrent Carcinoma of the Cervix Pembrolizumab - First-line Treatment of Advanced HER2-negative Esophageal, Gastric, and Esophagogastric Junction Carcinoma Pembrolizumab - In Combo w Platinum and Pemetrexed for First Line Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Pembrolizumab - In Combo w Carboplatin and Paclitaxel for First-Line Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC) Pembrolizumab (Adult and Pediatric) - Adjuvant Treatment for Completely Resected Stage IIB or IIC Melanoma Pembrolizumab - Advanced Melanoma (Unresectable or Metastatic Melanoma) and Prior Ipilimumab Pembrolizumab - Advanced Melanoma (Unresectable or Metastatic Melanoma) and No Prior Ipilimumab Pembrolizumab - Adjuvant Treatment for Non-Small Cell Lung Cancer Pembrolizumab (Adult and Pediatric) - Unresectable or Metastatic MSI-H or dMMR Advanced Solid Tumours Pembrolizumab - (Neo)Adjuvant Therapy for Resectable Non-Small Cell Lung Cancer Enfortumab Vedotin with Pembrolizumab - Previously Untreated Locally Advanced Unresectable or Metastatic Urothelial Cancer Pembrolizumab - Previously Untreated Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma Pembrolizumab - Primary Advanced or Recurrent Endometrial Carcinoma Pembrolizumab (Adult and Pediatric) - Adjuvant Treatment for Completely Resected Stage IIB or IIC Melanoma Pembrolizumab - (Neo)adjuvant Treatment for Completely Resectable Stage III or IV MelanomaPatient Info Sheet
Apr 2023
What it is used for
- For treating certain types of cancers such as skin (called melanoma), non-small cell lung, head and neck, renal cell (kidney), colorectal, endometrial, cervical, bladder or urinary tract, breast, esophageal and others. It is also used to treat some types of lymphomas.
- Pembrolizumab is an immunotherapy drug. For more information on immunotherapy, click here.